nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—SLC6A3—malignant glioma	0.878	1	CbGaD
Lisdexamfetamine—SLC18A2—telencephalic ventricle—malignant glioma	0.011	0.21	CbGeAlD
Lisdexamfetamine—SLC6A3—telencephalic ventricle—malignant glioma	0.0083	0.159	CbGeAlD
Lisdexamfetamine—SLC18A2—brainstem—malignant glioma	0.00297	0.0568	CbGeAlD
Lisdexamfetamine—SLC18A2—telencephalon—malignant glioma	0.00263	0.0504	CbGeAlD
Lisdexamfetamine—SLC6A3—brainstem—malignant glioma	0.00225	0.043	CbGeAlD
Lisdexamfetamine—Digestion impaired—Temozolomide—malignant glioma	0.0022	0.0444	CcSEcCtD
Lisdexamfetamine—SLC18A2—medulla oblongata—malignant glioma	0.00207	0.0396	CbGeAlD
Lisdexamfetamine—SLC6A3—telencephalon—malignant glioma	0.00199	0.0382	CbGeAlD
Lisdexamfetamine—SLC18A2—midbrain—malignant glioma	0.00189	0.0362	CbGeAlD
Lisdexamfetamine—SLC6A2—brainstem—malignant glioma	0.00181	0.0347	CbGeAlD
Lisdexamfetamine—SLC6A2—telencephalon—malignant glioma	0.00161	0.0308	CbGeAlD
Lisdexamfetamine—ADRA1B—central nervous system—malignant glioma	0.00151	0.029	CbGeAlD
Lisdexamfetamine—SLC18A2—central nervous system—malignant glioma	0.0015	0.0287	CbGeAlD
Lisdexamfetamine—SLC18A2—cerebellum—malignant glioma	0.00146	0.028	CbGeAlD
Lisdexamfetamine—SLC6A3—midbrain—malignant glioma	0.00143	0.0274	CbGeAlD
Lisdexamfetamine—SLC6A3—spinal cord—malignant glioma	0.0014	0.0267	CbGeAlD
Lisdexamfetamine—SLC6A2—medulla oblongata—malignant glioma	0.00126	0.0242	CbGeAlD
Lisdexamfetamine—ADRA1B—brain—malignant glioma	0.0012	0.023	CbGeAlD
Lisdexamfetamine—SLC18A2—Synaptic Vesicle Pathway—SYP—malignant glioma	0.00119	0.069	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—brain—malignant glioma	0.00119	0.0228	CbGeAlD
Lisdexamfetamine—SLC6A3—central nervous system—malignant glioma	0.00113	0.0217	CbGeAlD
Lisdexamfetamine—SLC6A3—cerebellum—malignant glioma	0.00111	0.0212	CbGeAlD
Lisdexamfetamine—Diplopia—Carmustine—malignant glioma	0.00111	0.0223	CcSEcCtD
Lisdexamfetamine—Diplopia—Temozolomide—malignant glioma	0.00107	0.0215	CcSEcCtD
Lisdexamfetamine—Affect lability—Temozolomide—malignant glioma	0.00105	0.0212	CcSEcCtD
Lisdexamfetamine—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—BCHE—malignant glioma	0.00103	0.0597	CbGpPWpGaD
Lisdexamfetamine—Toxic epidermal necrolysis—Temozolomide—malignant glioma	0.000962	0.0194	CcSEcCtD
Lisdexamfetamine—SLC6A2—central nervous system—malignant glioma	0.000914	0.0175	CbGeAlD
Lisdexamfetamine—SLC6A3—brain—malignant glioma	0.000899	0.0172	CbGeAlD
Lisdexamfetamine—Erectile dysfunction—Temozolomide—malignant glioma	0.00085	0.0171	CcSEcCtD
Lisdexamfetamine—Depression—Carmustine—malignant glioma	0.000849	0.0171	CcSEcCtD
Lisdexamfetamine—Weight increased—Temozolomide—malignant glioma	0.00084	0.0169	CcSEcCtD
Lisdexamfetamine—Weight decreased—Temozolomide—malignant glioma	0.000835	0.0168	CcSEcCtD
Lisdexamfetamine—Depression—Temozolomide—malignant glioma	0.000821	0.0165	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Temozolomide—malignant glioma	0.000816	0.0164	CcSEcCtD
Lisdexamfetamine—SLC18A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—malignant glioma	0.000815	0.0472	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Dopaminergic Neurogenesis—SOX2—malignant glioma	0.000793	0.0459	CbGpPWpGaD
Lisdexamfetamine—Hepatobiliary disease—Temozolomide—malignant glioma	0.000778	0.0157	CcSEcCtD
Lisdexamfetamine—Hallucination—Carmustine—malignant glioma	0.000761	0.0153	CcSEcCtD
Lisdexamfetamine—Selegiline—CYP2B6—malignant glioma	0.000749	0.308	CrCbGaD
Lisdexamfetamine—Hepatitis—Temozolomide—malignant glioma	0.000739	0.0149	CcSEcCtD
Lisdexamfetamine—Visual impairment—Carmustine—malignant glioma	0.000737	0.0149	CcSEcCtD
Lisdexamfetamine—Hallucination—Temozolomide—malignant glioma	0.000735	0.0148	CcSEcCtD
Lisdexamfetamine—SLC6A2—brain—malignant glioma	0.000726	0.0139	CbGeAlD
Lisdexamfetamine—Eye disorder—Carmustine—malignant glioma	0.000715	0.0144	CcSEcCtD
Lisdexamfetamine—Visual impairment—Temozolomide—malignant glioma	0.000712	0.0144	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Temozolomide—malignant glioma	0.000699	0.0141	CcSEcCtD
Lisdexamfetamine—Eye disorder—Temozolomide—malignant glioma	0.000691	0.0139	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Temozolomide—malignant glioma	0.000686	0.0138	CcSEcCtD
Lisdexamfetamine—Mental disorder—Carmustine—malignant glioma	0.00067	0.0135	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Temozolomide—malignant glioma	0.000667	0.0135	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Temozolomide—malignant glioma	0.000666	0.0134	CcSEcCtD
Lisdexamfetamine—Malnutrition—Carmustine—malignant glioma	0.000666	0.0134	CcSEcCtD
Lisdexamfetamine—Dextroamphetamine—SLC6A3—malignant glioma	0.000658	0.271	CrCbGaD
Lisdexamfetamine—Mental disorder—Temozolomide—malignant glioma	0.000647	0.013	CcSEcCtD
Lisdexamfetamine—Malnutrition—Temozolomide—malignant glioma	0.000643	0.013	CcSEcCtD
Lisdexamfetamine—Vision blurred—Carmustine—malignant glioma	0.000627	0.0126	CcSEcCtD
Lisdexamfetamine—Tremor—Carmustine—malignant glioma	0.000624	0.0126	CcSEcCtD
Lisdexamfetamine—Agitation—Carmustine—malignant glioma	0.000612	0.0123	CcSEcCtD
Lisdexamfetamine—Vision blurred—Temozolomide—malignant glioma	0.000606	0.0122	CcSEcCtD
Lisdexamfetamine—Tremor—Temozolomide—malignant glioma	0.000603	0.0121	CcSEcCtD
Lisdexamfetamine—Agitation—Temozolomide—malignant glioma	0.000591	0.0119	CcSEcCtD
Lisdexamfetamine—Angioedema—Temozolomide—malignant glioma	0.000588	0.0118	CcSEcCtD
Lisdexamfetamine—Convulsion—Carmustine—malignant glioma	0.000577	0.0116	CcSEcCtD
Lisdexamfetamine—Hypertension—Carmustine—malignant glioma	0.000575	0.0116	CcSEcCtD
Lisdexamfetamine—Palpitations—Temozolomide—malignant glioma	0.000568	0.0115	CcSEcCtD
Lisdexamfetamine—SLC18A2—Amine compound SLC transporters—SLC6A3—malignant glioma	0.000565	0.0327	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Dopaminergic Neurogenesis—SLC6A3—malignant glioma	0.000565	0.0327	CbGpPWpGaD
Lisdexamfetamine—Anxiety—Carmustine—malignant glioma	0.000565	0.0114	CcSEcCtD
Lisdexamfetamine—Convulsion—Temozolomide—malignant glioma	0.000557	0.0112	CcSEcCtD
Lisdexamfetamine—Hypertension—Temozolomide—malignant glioma	0.000555	0.0112	CcSEcCtD
Lisdexamfetamine—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—malignant glioma	0.000548	0.0317	CbGpPWpGaD
Lisdexamfetamine—Anxiety—Temozolomide—malignant glioma	0.000546	0.011	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000544	0.011	CcSEcCtD
Lisdexamfetamine—Dry mouth—Temozolomide—malignant glioma	0.000536	0.0108	CcSEcCtD
Lisdexamfetamine—Amphetamine—SLC6A3—malignant glioma	0.00053	0.218	CrCbGaD
Lisdexamfetamine—Tachycardia—Carmustine—malignant glioma	0.00053	0.0107	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Temozolomide—malignant glioma	0.000525	0.0106	CcSEcCtD
Lisdexamfetamine—Anorexia—Carmustine—malignant glioma	0.000518	0.0104	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Temozolomide—malignant glioma	0.000515	0.0104	CcSEcCtD
Lisdexamfetamine—Skin disorder—Temozolomide—malignant glioma	0.00051	0.0103	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Temozolomide—malignant glioma	0.000507	0.0102	CcSEcCtD
Lisdexamfetamine—Anorexia—Temozolomide—malignant glioma	0.0005	0.0101	CcSEcCtD
Lisdexamfetamine—Methamphetamine—SLC6A3—malignant glioma	0.000492	0.202	CrCbGaD
Lisdexamfetamine—Insomnia—Carmustine—malignant glioma	0.000491	0.0099	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Carmustine—malignant glioma	0.000484	0.00976	CcSEcCtD
Lisdexamfetamine—Somnolence—Carmustine—malignant glioma	0.000483	0.00973	CcSEcCtD
Lisdexamfetamine—Insomnia—Temozolomide—malignant glioma	0.000475	0.00957	CcSEcCtD
Lisdexamfetamine—SLC6A3—Dopaminergic Neurogenesis—SOX2—malignant glioma	0.000473	0.0274	CbGpPWpGaD
Lisdexamfetamine—Decreased appetite—Carmustine—malignant glioma	0.000472	0.00952	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Carmustine—malignant glioma	0.000469	0.00945	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Temozolomide—malignant glioma	0.000468	0.00943	CcSEcCtD
Lisdexamfetamine—Somnolence—Temozolomide—malignant glioma	0.000467	0.00941	CcSEcCtD
Lisdexamfetamine—Constipation—Carmustine—malignant glioma	0.000465	0.00936	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Temozolomide—malignant glioma	0.000462	0.00931	CcSEcCtD
Lisdexamfetamine—SLC6A3—Alpha-synuclein signaling—PARK2—malignant glioma	0.000457	0.0264	CbGpPWpGaD
Lisdexamfetamine—Decreased appetite—Temozolomide—malignant glioma	0.000456	0.0092	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000453	0.00913	CcSEcCtD
Lisdexamfetamine—Fatigue—Temozolomide—malignant glioma	0.000453	0.00912	CcSEcCtD
Lisdexamfetamine—Constipation—Temozolomide—malignant glioma	0.000449	0.00905	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Carmustine—malignant glioma	0.000429	0.00865	CcSEcCtD
Lisdexamfetamine—Urticaria—Temozolomide—malignant glioma	0.000417	0.00841	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Temozolomide—malignant glioma	0.000415	0.00836	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Carmustine—malignant glioma	0.0004	0.00807	CcSEcCtD
Lisdexamfetamine—Asthenia—Carmustine—malignant glioma	0.00039	0.00786	CcSEcCtD
Lisdexamfetamine—SLC6A3—Parkinsons Disease Pathway—PARK2—malignant glioma	0.000388	0.0225	CbGpPWpGaD
Lisdexamfetamine—Hypersensitivity—Temozolomide—malignant glioma	0.000387	0.00779	CcSEcCtD
Lisdexamfetamine—SLC6A2—Amine compound SLC transporters—SLC6A3—malignant glioma	0.00038	0.022	CbGpPWpGaD
Lisdexamfetamine—Asthenia—Temozolomide—malignant glioma	0.000377	0.00759	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Carmustine—malignant glioma	0.000372	0.00749	CcSEcCtD
Lisdexamfetamine—SLC6A2—Monoamine Transport—SLC6A3—malignant glioma	0.000361	0.0209	CbGpPWpGaD
Lisdexamfetamine—Dizziness—Carmustine—malignant glioma	0.000359	0.00724	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Temozolomide—malignant glioma	0.000359	0.00724	CcSEcCtD
Lisdexamfetamine—Dizziness—Temozolomide—malignant glioma	0.000347	0.007	CcSEcCtD
Lisdexamfetamine—Vomiting—Carmustine—malignant glioma	0.000345	0.00696	CcSEcCtD
Lisdexamfetamine—Rash—Carmustine—malignant glioma	0.000343	0.0069	CcSEcCtD
Lisdexamfetamine—Dermatitis—Carmustine—malignant glioma	0.000342	0.0069	CcSEcCtD
Lisdexamfetamine—Headache—Carmustine—malignant glioma	0.00034	0.00686	CcSEcCtD
Lisdexamfetamine—Vomiting—Temozolomide—malignant glioma	0.000334	0.00673	CcSEcCtD
Lisdexamfetamine—Rash—Temozolomide—malignant glioma	0.000331	0.00667	CcSEcCtD
Lisdexamfetamine—Dermatitis—Temozolomide—malignant glioma	0.000331	0.00666	CcSEcCtD
Lisdexamfetamine—Headache—Temozolomide—malignant glioma	0.000329	0.00663	CcSEcCtD
Lisdexamfetamine—Nausea—Carmustine—malignant glioma	0.000323	0.0065	CcSEcCtD
Lisdexamfetamine—Nausea—Temozolomide—malignant glioma	0.000312	0.00628	CcSEcCtD
Lisdexamfetamine—SLC6A2—NRF2 pathway—FTH1—malignant glioma	0.000282	0.0163	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—FTH1—malignant glioma	0.00025	0.0145	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—APOD—malignant glioma	0.000224	0.013	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—malignant glioma	0.000221	0.0128	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Alpha-synuclein signaling—BAD—malignant glioma	0.000196	0.0113	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Dopaminergic Neurogenesis—STAT3—malignant glioma	0.000193	0.0112	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—ATP1B2—malignant glioma	0.000187	0.0108	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—APOD—malignant glioma	0.000151	0.00875	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—malignant glioma	0.000149	0.00861	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Monoamine Transport—IL1B—malignant glioma	0.000147	0.00853	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—COX8A—malignant glioma	0.000147	0.00849	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—FTH1—malignant glioma	0.000134	0.00777	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—APOD—malignant glioma	0.000134	0.00775	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—BCHE—malignant glioma	0.000132	0.00763	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Monoamine Transport—IL1B—malignant glioma	0.000131	0.00756	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—PTK2—malignant glioma	0.000127	0.00738	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—SLC6A3—malignant glioma	0.000124	0.00717	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ATP1B2—malignant glioma	0.000117	0.00679	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Dopaminergic Neurogenesis—STAT3—malignant glioma	0.000115	0.00667	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—APOD—malignant glioma	0.000114	0.0066	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Parkinsons Disease Pathway—CASP3—malignant glioma	0.000113	0.00657	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—SLC5A5—malignant glioma	0.000113	0.00652	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—SLC6A3—malignant glioma	0.000107	0.00621	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Monoamine Transport—TNF—malignant glioma	0.000107	0.00619	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—SLC5A5—malignant glioma	0.000106	0.00611	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—BCHE—malignant glioma	0.000101	0.00585	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—SLC6A3—malignant glioma	0.0001	0.00582	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—SLC5A5—malignant glioma	9.98e-05	0.00578	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—COX8A—malignant glioma	9.87e-05	0.00571	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—SLC6A3—malignant glioma	9.49e-05	0.0055	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Monoamine Transport—TNF—malignant glioma	9.47e-05	0.00548	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—GSTP1—malignant glioma	9.08e-05	0.00525	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—FTH1—malignant glioma	9.03e-05	0.00523	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—YWHAE—malignant glioma	8.89e-05	0.00514	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—COX8A—malignant glioma	8.74e-05	0.00506	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PIK3CG—malignant glioma	8.7e-05	0.00504	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—MMP2—malignant glioma	8.19e-05	0.00474	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—GSTP1—malignant glioma	8.04e-05	0.00465	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—FTH1—malignant glioma	8e-05	0.00463	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—AKT2—malignant glioma	7.96e-05	0.00461	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—CCR4—malignant glioma	7.92e-05	0.00459	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ATP1B2—malignant glioma	7.89e-05	0.00457	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—BCHE—malignant glioma	7.86e-05	0.00455	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—APOD—malignant glioma	7.68e-05	0.00444	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PIK3CD—malignant glioma	7.65e-05	0.00443	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—GJA1—malignant glioma	7.3e-05	0.00423	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—PDGFB—malignant glioma	7.17e-05	0.00415	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—SLC5A5—malignant glioma	7.1e-05	0.00411	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—PIK3CB—malignant glioma	7.08e-05	0.0041	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ATP1B2—malignant glioma	6.99e-05	0.00405	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—BDKRB2—malignant glioma	6.97e-05	0.00403	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—CXCL8—malignant glioma	6.81e-05	0.00394	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—APOD—malignant glioma	6.8e-05	0.00394	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCR4—malignant glioma	6.79e-05	0.00393	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—SLC6A3—malignant glioma	6.76e-05	0.00391	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—BRAF—malignant glioma	6.73e-05	0.00389	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PIK3CB—malignant glioma	6.67e-05	0.00386	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—CASP3—malignant glioma	6.51e-05	0.00377	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—PDGFB—malignant glioma	6.36e-05	0.00368	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—KNG1—malignant glioma	6.34e-05	0.00367	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—SLC5A5—malignant glioma	6.29e-05	0.00364	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—BDKRB2—malignant glioma	6.23e-05	0.00361	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—MMP9—malignant glioma	6.16e-05	0.00356	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—BCHE—malignant glioma	6.02e-05	0.00348	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—CXCR3—malignant glioma	5.89e-05	0.00341	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—TFRC—malignant glioma	5.84e-05	0.00338	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—malignant glioma	5.67e-05	0.00328	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—MDM2—malignant glioma	5.64e-05	0.00326	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—RAF1—malignant glioma	5.62e-05	0.00325	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—BDKRB2—malignant glioma	5.38e-05	0.00312	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC5A5—malignant glioma	5.36e-05	0.0031	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CCR4—malignant glioma	5.17e-05	0.00299	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—BRAF—malignant glioma	5.15e-05	0.00298	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC6A3—malignant glioma	5.1e-05	0.00296	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCR3—malignant glioma	5.04e-05	0.00292	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—malignant glioma	5.02e-05	0.00291	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—EGFR—malignant glioma	4.97e-05	0.00288	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—BDKRB2—malignant glioma	4.61e-05	0.00267	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LATS2—malignant glioma	4.42e-05	0.00256	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—MDM2—malignant glioma	4.32e-05	0.0025	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—RAF1—malignant glioma	4.3e-05	0.00249	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—KNG1—malignant glioma	4.2e-05	0.00243	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—F2—malignant glioma	4.1e-05	0.00237	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PIK3CA—malignant glioma	4.07e-05	0.00235	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—BRAF—malignant glioma	4.01e-05	0.00232	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—TP53—malignant glioma	3.93e-05	0.00228	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—TFRC—malignant glioma	3.93e-05	0.00227	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CXCR3—malignant glioma	3.84e-05	0.00222	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (12/13) signalling events—PIK3CA—malignant glioma	3.8e-05	0.0022	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—F2—malignant glioma	3.66e-05	0.00212	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC5A5—malignant glioma	3.61e-05	0.00209	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—AKT1—malignant glioma	3.53e-05	0.00204	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—BDKRB2—malignant glioma	3.51e-05	0.00203	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—TFRC—malignant glioma	3.48e-05	0.00202	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—malignant glioma	3.44e-05	0.00199	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC6A3—malignant glioma	3.43e-05	0.00199	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—MDM2—malignant glioma	3.36e-05	0.00194	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—RAF1—malignant glioma	3.35e-05	0.00194	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LATS1—malignant glioma	3.35e-05	0.00194	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—AKT1—malignant glioma	3.32e-05	0.00192	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC5A5—malignant glioma	3.2e-05	0.00185	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—KNG1—malignant glioma	3.2e-05	0.00185	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—BRAF—malignant glioma	3.07e-05	0.00178	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CCR4—malignant glioma	2.92e-05	0.00169	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—malignant glioma	2.75e-05	0.00159	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—F2—malignant glioma	2.71e-05	0.00157	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCR4—malignant glioma	2.65e-05	0.00154	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—MDM2—malignant glioma	2.57e-05	0.00149	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—RAF1—malignant glioma	2.56e-05	0.00148	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—RAF1—malignant glioma	2.31e-05	0.00134	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MDK—malignant glioma	2.26e-05	0.00131	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CXCR3—malignant glioma	2.17e-05	0.00126	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—DTX1—malignant glioma	2.16e-05	0.00125	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—F2—malignant glioma	2.07e-05	0.0012	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—BDKRB2—malignant glioma	1.99e-05	0.00115	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CXCR3—malignant glioma	1.97e-05	0.00114	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—malignant glioma	1.91e-05	0.00111	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—malignant glioma	1.89e-05	0.00109	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—PIK3CA—malignant glioma	1.83e-05	0.00106	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—KNG1—malignant glioma	1.81e-05	0.00105	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—BDKRB2—malignant glioma	1.8e-05	0.00104	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—malignant glioma	1.78e-05	0.00103	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SUFU—malignant glioma	1.71e-05	0.000992	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HEY2—malignant glioma	1.69e-05	0.00098	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GFAP—malignant glioma	1.65e-05	0.000957	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—KNG1—malignant glioma	1.64e-05	0.00095	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—malignant glioma	1.64e-05	0.000948	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SPHK1—malignant glioma	1.6e-05	0.000926	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HEY1—malignant glioma	1.57e-05	0.000907	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCR4—malignant glioma	1.57e-05	0.000907	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—RAF1—malignant glioma	1.56e-05	0.000901	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HIST1H3B—malignant glioma	1.52e-05	0.000881	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CXCL8—malignant glioma	1.46e-05	0.000843	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—MMP3—malignant glioma	1.45e-05	0.000841	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—JAG2—malignant glioma	1.39e-05	0.000805	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—RAF1—malignant glioma	1.38e-05	0.000798	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—H3F3A—malignant glioma	1.18e-05	0.000681	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—F2—malignant glioma	1.17e-05	0.000676	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CXCR3—malignant glioma	1.16e-05	0.000674	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—YWHAE—malignant glioma	1.13e-05	0.000656	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NTRK2—malignant glioma	1.13e-05	0.000656	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FLT1—malignant glioma	1.13e-05	0.000653	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—DUSP6—malignant glioma	1.12e-05	0.00065	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CG—malignant glioma	1.12e-05	0.000647	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—JAG1—malignant glioma	1.11e-05	0.000642	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NOTCH3—malignant glioma	1.1e-05	0.000639	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FBXW7—malignant glioma	1.09e-05	0.000629	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—BDKRB2—malignant glioma	1.07e-05	0.000617	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—F2—malignant glioma	1.06e-05	0.000614	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AKT2—malignant glioma	1.02e-05	0.000592	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CG—malignant glioma	1.01e-05	0.000587	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PTPN11—malignant glioma	9.97e-06	0.000577	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NOTCH2—malignant glioma	9.9e-06	0.000573	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CD—malignant glioma	9.82e-06	0.000569	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KNG1—malignant glioma	9.69e-06	0.000561	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AKT2—malignant glioma	9.28e-06	0.000537	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NTRK1—malignant glioma	9.23e-06	0.000535	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CD—malignant glioma	8.92e-06	0.000516	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MMP3—malignant glioma	8.59e-06	0.000497	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CB—malignant glioma	8.56e-06	0.000496	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CDKN2B—malignant glioma	8.51e-06	0.000493	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTK2—malignant glioma	8.26e-06	0.000478	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CXCL8—malignant glioma	8.23e-06	0.000476	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HES1—malignant glioma	8.12e-06	0.00047	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NCOR1—malignant glioma	8.07e-06	0.000467	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—RAF1—malignant glioma	7.96e-06	0.000461	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—IL2—malignant glioma	7.86e-06	0.000455	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CB—malignant glioma	7.77e-06	0.00045	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PDGFRA—malignant glioma	7.73e-06	0.000448	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SPP1—malignant glioma	7.5e-06	0.000434	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CXCL8—malignant glioma	7.47e-06	0.000433	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL2—malignant glioma	7.14e-06	0.000413	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TERT—malignant glioma	7.11e-06	0.000412	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PDGFB—malignant glioma	6.94e-06	0.000402	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FGFR1—malignant glioma	6.91e-06	0.0004	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HIF1A—malignant glioma	6.8e-06	0.000394	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CAV1—malignant glioma	6.58e-06	0.000381	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KDR—malignant glioma	6.51e-06	0.000377	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FN1—malignant glioma	6.26e-06	0.000363	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—F2—malignant glioma	6.26e-06	0.000363	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—BAD—malignant glioma	6.19e-06	0.000358	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NOTCH1—malignant glioma	6.13e-06	0.000355	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CD80—malignant glioma	6e-06	0.000348	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—APC—malignant glioma	5.99e-06	0.000347	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CG—malignant glioma	5.99e-06	0.000347	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EGF—malignant glioma	5.92e-06	0.000343	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTPN11—malignant glioma	5.89e-06	0.000341	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—BRAF—malignant glioma	5.63e-06	0.000326	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKT2—malignant glioma	5.48e-06	0.000317	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—EGFR—malignant glioma	5.46e-06	0.000316	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CD—malignant glioma	5.27e-06	0.000305	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CA—malignant glioma	5.22e-06	0.000302	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—KRAS—malignant glioma	5.16e-06	0.000299	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FGF2—malignant glioma	5.04e-06	0.000292	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CA—malignant glioma	4.74e-06	0.000274	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MDM2—malignant glioma	4.72e-06	0.000273	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RAF1—malignant glioma	4.7e-06	0.000272	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ERBB2—malignant glioma	4.65e-06	0.000269	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CB—malignant glioma	4.59e-06	0.000266	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CXCL8—malignant glioma	4.41e-06	0.000256	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AKT1—malignant glioma	4.26e-06	0.000247	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CASP3—malignant glioma	4.22e-06	0.000245	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL2—malignant glioma	4.22e-06	0.000244	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MMP9—malignant glioma	3.99e-06	0.000231	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTEN—malignant glioma	3.97e-06	0.00023	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AKT1—malignant glioma	3.87e-06	0.000224	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VEGFA—malignant glioma	3.58e-06	0.000208	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—STAT3—malignant glioma	3.55e-06	0.000205	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MYC—malignant glioma	3.3e-06	0.000191	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EGFR—malignant glioma	3.23e-06	0.000187	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KRAS—malignant glioma	3.05e-06	0.000176	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CA—malignant glioma	2.8e-06	0.000162	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TP53—malignant glioma	2.71e-06	0.000157	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKT1—malignant glioma	2.29e-06	0.000132	CbGpPWpGaD
